BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study Journal Article

  


Authors: Rodriguez, C.; Rodriguez, T.; Kentos, A.; Driessen, C.; Suanmi, K.; Lesokhin, A. M.; Yee, A. J.; Minella, A. C.; Maraboina, R.; Upreti, V. V.; Zhou, D.; Shabooti, M.; Stieglmaier, J.; Quach, H.
Article Title: BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Abstract: AMG 420 is a first-in-class bispecific T-cell engager (BiTE®) molecule directing a cytotoxic T-cell response toward multiple myeloma cells. This phase 1b, open-label, dose-expansion study (NCT03836053) evaluated the safety, tolerability, and efficacy of AMG 420 monotherapy in patients with relapsed/refractory multiple myeloma. Twenty-three patients received continuous intravenous infusion of AMG 420 (200–600 μg/day) in a 6-week cycle. Two dose-limiting toxicities (grade 3 staphylococcal sepsis and recurrent grade 2 cytokine release syndrome [CRS]) were reported. Commonly reported treatment-related adverse events included CRS, headache, and pyrexia. Overall response rate was 34.8%; median progression-free survival was 2.83 months; and minimal residual disease–negative complete responses were reported in 8.7% of patients. Overall, the safety profile and efficacy from AMG 420 established the proof-of-concept of T-cell engager therapy as a promising therapeutic class in multiple myeloma and BCMA as an effective target for T-cell engager therapy. © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Keywords: multiple myeloma; b-cell maturation antigen; bispecific t-cell engager
Journal Title: Leukemia and Lymphoma
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Publication status: Online ahead of print
Date Published: 2025-01-01
Online Publication Date: 2025-01-01
Language: English
DOI: 10.1080/10428194.2025.2528115
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-105011265772&doi=10.1080%2f10428194.2025.2528115&partnerID=40&md5=3760b8415e6315cf9dc9ef24b505125d
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
Related MSK Work